Alaunos Therapeutics (TCRT) Accumulated Depreciation & Amortization (2016 - 2024)
Alaunos Therapeutics (TCRT) has disclosed Accumulated Depreciation & Amortization for 13 consecutive years, with $15000.0 as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Accumulated Depreciation & Amortization rose 15.38% year-over-year to $15000.0, compared with a TTM value of $15000.0 through Dec 2024, up 15.38%, and an annual FY2024 reading of $15000.0, up 15.38% over the prior year.
- Accumulated Depreciation & Amortization was $15000.0 for Q4 2024 at Alaunos Therapeutics, up from $13000.0 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $9.8 million in Q4 2022 and bottomed at $13000.0 in Q4 2023.
- Average Accumulated Depreciation & Amortization over 5 years is $4.4 million, with a median of $5.0 million recorded in 2020.
- The sharpest move saw Accumulated Depreciation & Amortization soared 49.4% in 2021, then crashed 99.87% in 2023.
- Year by year, Accumulated Depreciation & Amortization stood at $5.0 million in 2020, then skyrocketed by 49.4% to $7.4 million in 2021, then surged by 32.29% to $9.8 million in 2022, then plummeted by 99.87% to $13000.0 in 2023, then increased by 15.38% to $15000.0 in 2024.
- Business Quant data shows Accumulated Depreciation & Amortization for TCRT at $15000.0 in Q4 2024, $13000.0 in Q4 2023, and $9.8 million in Q4 2022.